Recent Updates
Recently added Catalysts

Nuvalent, Inc.

NUVL
Pharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$123.96
▲ 0 · 0%

Last traded Jul 14, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full NUVL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $70.2552W HIGH $113.02
Volume
3.07 M
Value Traded
133.89 M
Short % Float
1.53%
-1.35%Week
-5.24%1 Month
-1.17%3 Month
-4.52%6 Month
+464.2%5 Year
+464.2%All Time

Cash Data

Unlock NUVL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.07 B
EPS (TTM)
-6.06
P/E Ratio
-
Ent. Value
6.78 B
Total Shares
67.26 M
Float Shares
46.81 M
Insiders
32.95%
Institutions
72.61%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every NUVL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

NUVL Catalyst Timeline

Dated clinical, regulatory and corporate events for Nuvalent, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Nuvalent, Inc.

320Total events
10Upcoming
49Tier-1 (high impact)
2021 to 2028Coverage

Upcoming catalysts 2

T1PDUFA Date
Subscribe to view catalyst details
T1NDA Submission
Subscribe to view catalyst details

Event history 50

◆Timing GuidanceZidesamtinibApprovedPresentation
Submission for potential indication expansion of zidesamtinib in TKI-naive ROS1-positive NSCLC
TKI-naive advanced ROS1-positive NSCLCsource ↗
▲AcquiredCorporate
GSK announces agreement to acquire Nuvalent for $10.6 billion
source ↗
◆Poster PresentationZidesamtinibApprovedPresentation
Poster presentation of preliminary data for zidesamtinib in ROS1-positive solid tumors other than NSCLC at ASCO 2026
advanced ROS1-positive solid tumors other than NSCLCsource ↗
◆Oral PresentationNeladalkibFiledPresentation
Pivotal data for neladalkib in TKI pre-treated advanced ALK+ NSCLC at ASCO 2026
ALK-positive non-small cell lung cancersource ↗
▲FDA Filing AcceptedNeladalkibFiledRegulatory Filing
NDA for neladalkib accepted for filing with Priority Review
TKI pre-treated advanced ALK-positive NSCLCsource ↗
▲Management ChangeCorporate
Georg Pirmin Meyer joins as Chief International Officer
source ↗
▲FDA Filing AcceptedZidesamtinibApprovedRegulatory Filing
NDA for zidesamtinib accepted for filing
TKI pre-treated advanced ROS1-positive NSCLCsource ↗
▲FDA Filing AcceptedZidesamtinibApprovedRegulatory Filing
FDA accepted NDA filing for zidesamtinib in ROS1-positive NSCLC
locally advanced or metastatic ROS1-positive NSCLC after at least 1 prior ROS1 TKIsource ↗
●NDA SubmissionNeladalkibFiledRegulatory Filing
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
TKI pre-treated advanced ALK-positive NSCLCsource ↗
●Quarterly UpdateCorporate
First quarter 2026 financial results reported
source ↗
Unlock the full NUVL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How NUVL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-07-22zidesamtinib PDUFA Date ApprovedPDUFA
Unlock 5 more NUVL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C51 / 100
Pipeline Score
$1.8B
Pipeline Value
Not rated
Valuation Signal
3
Drugs Scored
-
rNPV / MCap
Nuvalent, Inc. carries a moderate pipeline score (51/100), with $2.8B risk-adjusted pipeline value, led by Neladalkib in Non-small Cell Lung Cancer (Phase 3).
Showing 1 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Neladalkib Small moleculeNCT06765109Non-small Cell Lung CancerPhase 3 RECRUITING 450Dec 1, 2029
Unlock the NUVL pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every NUVL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
neladalkib
BreakthroughOrphan
advanced ALK-positive NSCLCPhase 1/22026-05-21encouraging activity in TKI pre-treated patientsRead MoreNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...Read More
Scroll for more · summaries link to the source press release
Unlock every NUVL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock NUVL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Meyers Michael L.DirectorDisposition due to tender of shares -5,146 $124.00 07/15/2026
Unlock the full NUVL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in NUVL

Fund % of Portfolio Current MV Shares Owned Activity
Paradigm Biocapital Advisors LP 13.7 % (23.4 %) 731.67 M 5.92 M 11.27% ( 600.00 K)
Unlock every fund holding NUVL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in NUVL
Shares held by hedge funds each quarter, and who bought or sold.

NUVL Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock NUVL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live NUVL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock NUVL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How NUVL ranks across every disease it competes in

Competitive Position is a premium feature
See how NUVL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

NUVL News

About Nuvalent, Inc.

Cambridge, MA 228 employees nuvalent.com
HeadquartersONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next NUVL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime